bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures 1-9, Tables 1-3 from Spatiotemporal Heterogeneity Characterizes the Genetic Landscape of Pheochromocytoma and Defines Early Events in Tumorigenesis
Authors: Crona Joakim , Backman Samuel , Maharjan Rajani , Mayrhofer Markus , Stålberg Peter , Isaksson Anders , Hellman Per , Björklund Peyman
Published: April 2023

Supplementary Figures 1-9, Tables 1-3. Supplementary Figure 1 Overview of the workflow executed in the current study. Supplementary Figure 2 Summary of the utilized sequencing workflow. Supplementary Figures 3A-B Sequencing reads and chromatograms from tumor and normal tissue showing (A)validation of H-RAS, RET and VHL mutations. Figure 3B presents data from patient 29 that had previously been determined as wild type in the VHL locus by Sanger Sequencing analysis. Supplementary Figure 4 Validation of NF1 mutations that was determined to cause a splice site disruption by in silico analysis Supplementary Figure 5. Standard curve showing relationship between copy number and Log R ratio generated by all segments included samples and arrays. Supplementary Figure 6 Correlation of study observations and ASCAT analysis in estimating the total fraction of tumor cells within each individual tumor sample. ASCAT could not determine the tumor purity for two samples. Supplementary Figure 7 Correlation of results from histopathological investigation and ASCAT in estimating the total fraction of tumor cells. Pearson correlation test R=0.658. Supplementary Figure 8 Correlation between TAPS and the study workflow in the estimation of clonal fractions for specific segments Supplementary Figure 9A and B. (A) correlation of allele frequencies of germline SNPs between SNP array and deeps sequencing methods. (B) relative difference between SNP array and deep sequencing variant frequencies dependent on deep sequencing read coverage. Supplementary table 1. Sequence coverage of targeted NGS Supplementary table 2. Statistical correlations Supplementary Table 3. Statistics on a tumor lesion bases
Supplemental Tables 1-2, Figures 1-3 from Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning
Authors: Hannon Muriel , Beguin Yves , Ehx Grégory , Servais Sophie , Seidel Laurence , Graux Carlos , Maertens Johan , Kerre Tessa , Daulne Coline , de Bock Muriel , Fillet Marianne , Ory Aurélie , Willems Evelyne , Gothot André , Humblet-Baron Stéphanie , Baron Frédéric
Published: April 2023

Supplemental Tables 1-2, Figures 1-3. Supplemental table 1. Patient characteristics Supplemental table 2. Comparison of patient characteristics and transplantation outcomes in patients included in the multicentre randomized study (n=94) (reported in reference #(3)) and included (n=53) or not (n=41) in the immune reconstitution sub-study reported here. Supplemental Figure 1. A) Evolution of serum IL-15 levels the first 28 days after transplantation in TBI (black boxes, n=14) and TLI (white boxes, n=13) patients. B) Serum cytokine levels on day 28 after transplantation in TBI (n=14) and TLI (n=13) patients. C)Day-28 serum IL-4/CD4+ T cell ratios in TBI (n=14) and TLI (n=12) patients. In the different subfigures, * means p<0.05, ** means p<0.01 and *** means p<0.001. Supplemental Figure 2. A) Kinetics of donor T cell chimerism in TBI (black boxes) and TLI (white boxes) patients. B) Cumulative incidence of moderate/severe chronic GVHD in TBI (broken line) and TLI (solid line) patients (P=0.02). C) Cumulative incidence of relapse/progression in TBI (broken line) and TLI (solid line) patients (P=0.01). D)Cumulative incidence of CMV infection in TBI (broken line) and TLI (solid line) patients (P<0.001). * means p<0.05, ** means p<0.01 and *** means p<0.001. Supplemental Figure 3. A-F) Recovery of B and NK cell subsets in TBI (black boxes) and TLI (white boxes) patients.
Supplementary Figure 6 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18
Authors: Ma Zhifeng , Li Wen , Yoshiya Shinichi , Xu Yunfeng , Hata Masaki , El-Darawish Yosif , Markova Tzvetanka , Yamanishi Kyosuke , Yamanishi Hiromichi , Tahara Hideaki , Tanaka Yoshimasa , Okamura Haruki
Published: April 2023

Cytokine production by PECs from pre-implanted mice receiving immune checkpoint blockade plus IL-18 and/or αGM1
Supplementary Figure 2 from NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma
Authors: Lai Robin Kit-Ho , Xu Iris Ming-Jing , Chiu David Kung-Chun , Tse Aki Pui-Wah , Wei Larry Lai , Law Cheuk-Ting , Lee Derek , Wong Chun-Ming , Wong Maria Pik , Ng Irene Oi-Lin , Wong Carmen Chak-Lui
Published: April 2023

Figure S2. Knockdown of HIF-1α or HIF-2α, and knockout of HIF-1α are confirmed by western blot analysis.
Supplemental Figure Legends from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18
Authors: Ma Zhifeng , Li Wen , Yoshiya Shinichi , Xu Yunfeng , Hata Masaki , El-Darawish Yosif , Markova Tzvetanka , Yamanishi Kyosuke , Yamanishi Hiromichi , Tahara Hideaki , Tanaka Yoshimasa , Okamura Haruki
Published: April 2023

Supplemental Figure Legends
Supplementary Table S2 from Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Authors: Arena Sabrina , Bellosillo Beatriz , Siravegna Giulia , Martínez Alejandro , Cañadas Israel , Lazzari Luca , Ferruz Noelia , Russo Mariangela , Misale Sandra , González Iria , Iglesias Mar , Gavilan Elena , Corti Giorgio , Hobor Sebastijan , Crisafulli Giovanni , Salido Marta , Sánchez Juan , Dalmases Alba , Bellmunt Joaquim , De Fabritiis Gianni , Rovira Ana , Di Nicolantonio Federica , Albanell Joan , Bardelli Alberto , Montagut Clara
Published: April 2023

Supplementary Table S2. Validation of ddPCR probes.
Supplemental Table 3 from AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Authors: Brand Toni M. , Iida Mari , Stein Andrew P. , Corrigan Kelsey L. , Braverman Cara M. , Coan John P. , Pearson Hannah E. , Bahrar Harsh , Fowler Tyler L. , Bednarz Bryan P. , Saha Sandeep , Yang David , Gill Parkash S. , Lingen Mark W. , Saloura Vassiliki , Villaflor Victoria M. , Salgia Ravi , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Supplemental Table 3. Fractional cell proliferation analysis for drug combination synergy
Supplementary Table S1 from Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Authors: Arena Sabrina , Bellosillo Beatriz , Siravegna Giulia , Martínez Alejandro , Cañadas Israel , Lazzari Luca , Ferruz Noelia , Russo Mariangela , Misale Sandra , González Iria , Iglesias Mar , Gavilan Elena , Corti Giorgio , Hobor Sebastijan , Crisafulli Giovanni , Salido Marta , Sánchez Juan , Dalmases Alba , Bellmunt Joaquim , De Fabritiis Gianni , Rovira Ana , Di Nicolantonio Federica , Albanell Joan , Bardelli Alberto , Montagut Clara
Published: April 2023

Supplementary Table S1. Clinical characteristics of patients.
Supplemental Materials and Methods from AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Authors: Brand Toni M. , Iida Mari , Stein Andrew P. , Corrigan Kelsey L. , Braverman Cara M. , Coan John P. , Pearson Hannah E. , Bahrar Harsh , Fowler Tyler L. , Bednarz Bryan P. , Saha Sandeep , Yang David , Gill Parkash S. , Lingen Mark W. , Saloura Vassiliki , Villaflor Victoria M. , Salgia Ravi , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Supplemental Materials and Methods
Supplemental Figure 2 from AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Authors: Brand Toni M. , Iida Mari , Stein Andrew P. , Corrigan Kelsey L. , Braverman Cara M. , Coan John P. , Pearson Hannah E. , Bahrar Harsh , Fowler Tyler L. , Bednarz Bryan P. , Saha Sandeep , Yang David , Gill Parkash S. , Lingen Mark W. , Saloura Vassiliki , Villaflor Victoria M. , Salgia Ravi , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Supplemental Figure 2. HNSCC cell proliferation and apoptosis are not significantly impacted 24 hours post R428 treatment
Supplementary Table 1 from Pancreatic Cancer–Derived Exosomes Cause Paraneoplastic β-cell Dysfunction
Authors: Javeed Naureen , Sagar Gunisha , Dutta Shamit K. , Smyrk Thomas C. , Lau Julie S. , Bhattacharya Santanu , Truty Mark , Petersen Gloria M. , Kaufman Randal J. , Chari Suresh T. , Mukhopadhyay Debabrata
Published: April 2023

Supplementary Table 1. Pharmacological Inhibitors of Endocytic Pathways
Supplementary Fig. 5 from Pancreatic Cancer–Derived Exosomes Cause Paraneoplastic β-cell Dysfunction
Authors: Javeed Naureen , Sagar Gunisha , Dutta Shamit K. , Smyrk Thomas C. , Lau Julie S. , Bhattacharya Santanu , Truty Mark , Petersen Gloria M. , Kaufman Randal J. , Chari Suresh T. , Mukhopadhyay Debabrata
Published: April 2023

Supplementary Fig. 5. Adrenomedullin increases reactive oxygen species production. Reactive oxygen/nitrogen species (ROS/RNS) were detected in INS-1 cells pre-treated with either 1 or 20 pM adrenomedullin for 24 hours. The orange filter detects superoxide and nitric oxide generation, while the green filter detects all reactive oxygen species. Positive control cells were treated with Pyocyanin (Pyo) to induce ROS production and negative control cells were treated with Pyo + N-acetyl-L-cysteine (NAC) to inhibit ROS production. Scale bar represents 10 Ã‚Âµm.
Supplementary Methods from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Authors: Mangsbo Sara M. , Broos Sissela , Fletcher Erika , Veitonmäki Niina , Furebring Christina , Dahlén Eva , Norlén Per , Lindstedt Malin , Tötterman Thomas H. , Ellmark Peter
Published: April 2023

Supplementary Methods
Supplementary Fig. 4 from Pancreatic Cancer–Derived Exosomes Cause Paraneoplastic β-cell Dysfunction
Authors: Javeed Naureen , Sagar Gunisha , Dutta Shamit K. , Smyrk Thomas C. , Lau Julie S. , Bhattacharya Santanu , Truty Mark , Petersen Gloria M. , Kaufman Randal J. , Chari Suresh T. , Mukhopadhyay Debabrata
Published: April 2023

Supplementary Fig. 4. AM and PC-Exosomes modestly upregulate insulin gene expression. All studies were done using INS-1, a rat ÃŽÂ²-cell line. (A) Relative expression of insulin genes INS1 and INS2 in response to varying concentrations (1, 20, or 40 pM) of AM and AM inhibitor AM 22-52. (B) Western blot analysis of insulin protein output in response to 1, 20, or 40 pM of AM. 20 Ã‚Âµg of protein lysate was loaded. (C) Relative expression of insulin genes INS1 and INS2 in response to the addition of 50 Ã‚Âµg of PC-Exo. * P<.05; ** P<.001; *** P<.0001.
Supplementary Fig. 1 from Pancreatic Cancer–Derived Exosomes Cause Paraneoplastic β-cell Dysfunction
Authors: Javeed Naureen , Sagar Gunisha , Dutta Shamit K. , Smyrk Thomas C. , Lau Julie S. , Bhattacharya Santanu , Truty Mark , Petersen Gloria M. , Kaufman Randal J. , Chari Suresh T. , Mukhopadhyay Debabrata
Published: April 2023

Supplementary Fig. 1. NanoTracker results of PC-Exosome isolated from PC patient-derived cell lines and patient plasma. (A-B) PC-Exo isolated from a PC patient-derived cell line show the majority of microparticles are of exosomal size ([A] mode, 105{plus minus}4.2 nm). In (B), microparticles are more of microvesicle size (mode, 294{plus minus}13.5 nm). Thus, depending on the cell line, a 100,000 x g isolation can yield both exosomes and microvesicles. (C-F) PC-Exo isolated from the plasma of different PC patients show that the majority of microparticles in plasma are exosomes (modes, 156{plus minus}8.6 nm; 88{plus minus}5.0 nm; 92{plus minus}3.1 nm; 100{plus minus}7.0 nm, respectively). Analysis was taken by averaging 5, 60-second movies.
Supplemental figures 1-3 from Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy
Authors: Paez-Ribes Marta , Man Shan , Xu Ping , Kerbel Robert S.
Published: April 2023

Supplemental figures 1-3. Supplemental figure 1. Addition of chemotherapy enhances tumor growth inhibition and blocks local tumor invasion. Supplemental figure 2. Cyclophosphamide, when added to antiangiogenic therapy, inhibits tumor growth and blocks local tumor invasion. Supplemental figure 3. Reduced doses of DC101 had milder effects on local tumor invasion.
Supplemental figure legend from A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
Authors: Ko Andrew H. , Bekaii-Saab Tanios , Van Ziffle Jessica , Mirzoeva Olga M. , Joseph Nancy M. , Talasaz AmirAli , Kuhn Peter , Tempero Margaret A. , Collisson Eric A. , Kelley R. Kate , Venook Alan P. , Dito Elizabeth , Ong Anna , Ziyeh Sharvina , Courtin Ryan , Linetskaya Regina , Tahiri Sanaa , Korn W. Michael
Published: April 2023

Supplemental figure legend
Supplemental figure 1 from A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
Authors: Ko Andrew H. , Bekaii-Saab Tanios , Van Ziffle Jessica , Mirzoeva Olga M. , Joseph Nancy M. , Talasaz AmirAli , Kuhn Peter , Tempero Margaret A. , Collisson Eric A. , Kelley R. Kate , Venook Alan P. , Dito Elizabeth , Ong Anna , Ziyeh Sharvina , Courtin Ryan , Linetskaya Regina , Tahiri Sanaa , Korn W. Michael
Published: April 2023

Supplemental figure 1. Abdominal CT scans from a patient who achieved minor response following 2 cycles of treatment. Representative sections from baseline (left) and on-treatment (right) scans are shown.
Supplementary Figure 1 from Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response
Authors: Kuo Peiwen , Bratman Scott V. , Shultz David B. , von Eyben Rie , Chan Cato , Wang Ziwei , Say Carmen , Gupta Aparna , Loo Bill W. , Giaccia Amato J. , Koong Albert C. , Diehn Maximilian , Le Quynh-Thu
Published: April 2023

A schematic of tumor/host combinations showing Gal-1 WT and null C57Bl6/mice subcutaneous injection with Wt and shGal-1 LLC1 cells, time line of cell injection, tumor irradiation and blood collection time points. The relative plasma Gal-1 levels for each treatment group is also shown.
Supplementary Table 3 from Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate
Authors: Attard Gerhardt , de Bono Johann S. , Logothetis Christopher J. , Fizazi Karim , Mukherjee Som D. , Joshua Anthony M. , Schrijvers Dirk , van den Eertwegh Alfons J.M. , Li Weimin , Molina Arturo , Griffin Thomas W. , Kheoh Thian , Ricci Deborah S. , Zelinsky Kathy , Rathkopf Dana E. , Scher Howard I. , Ryan Charles J.
Published: April 2023

Supplementary Table 3. PSA decline by ERG class
Supplemental Materials and Methods from Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use
Authors: Srivastava Apurva K. , Jaganathan Soumya , Stephen Laurie , Hollingshead Melinda G. , Layhee Adam , Damour Eric , Govindharajulu Jeevan Prasaad , Donohue Jennifer , Esposito Dominic , Mapes James P. , Kinders Robert J. , Takebe Naoko , Tomaszewski Joseph E. , Kummar Shivaani , Doroshow James H. , Parchment Ralph E.
Published: April 2023

This file contains supplemental materials and methods describing protein calibrator preparation and pre-analytical variability
Supplemental Figure S2 from Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use
Authors: Srivastava Apurva K. , Jaganathan Soumya , Stephen Laurie , Hollingshead Melinda G. , Layhee Adam , Damour Eric , Govindharajulu Jeevan Prasaad , Donohue Jennifer , Esposito Dominic , Mapes James P. , Kinders Robert J. , Takebe Naoko , Tomaszewski Joseph E. , Kummar Shivaani , Doroshow James H. , Parchment Ralph E.
Published: April 2023

This file contains supplemental Figure S2: Temperature stability of analytes
supplemental legend from Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS
Authors: Yoshitake Yoshihiro , Fukuma Daiki , Yuno Akira , Hirayama Masatoshi , Nakayama Hideki , Tanaka Takuya , Nagata Masashi , Takamune Yasuo , Kawahara Kenta , Nakagawa Yoshihiro , Yoshida Ryoji , Hirosue Akiyuki , Ogi Hidenao , Hiraki Akimitsu , Jono Hirofumi , Hamada Akinobu , Yoshida Koji , Nishimura Yasuharu , Nakamura Yusuke , Shinohara Masanori
Published: April 2023

supplemental legend
Supplemental Figure S1 from Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use
Authors: Srivastava Apurva K. , Jaganathan Soumya , Stephen Laurie , Hollingshead Melinda G. , Layhee Adam , Damour Eric , Govindharajulu Jeevan Prasaad , Donohue Jennifer , Esposito Dominic , Mapes James P. , Kinders Robert J. , Takebe Naoko , Tomaszewski Joseph E. , Kummar Shivaani , Doroshow James H. , Parchment Ralph E.
Published: April 2023

This file contains supplemental Figure S1: Specificity of antibodies used in multiplex assays
Figure S2 from Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS
Authors: Yoshitake Yoshihiro , Fukuma Daiki , Yuno Akira , Hirayama Masatoshi , Nakayama Hideki , Tanaka Takuya , Nagata Masashi , Takamune Yasuo , Kawahara Kenta , Nakagawa Yoshihiro , Yoshida Ryoji , Hirosue Akiyuki , Ogi Hidenao , Hiraki Akimitsu , Jono Hirofumi , Hamada Akinobu , Yoshida Koji , Nishimura Yasuharu , Nakamura Yusuke , Shinohara Masanori
Published: April 2023

Figure S2. Chronological changes of peptide-specific CTL response determined by ELISPOT and pentamer assays in 24 patients investigated.
Figure S1 from Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS
Authors: Yoshitake Yoshihiro , Fukuma Daiki , Yuno Akira , Hirayama Masatoshi , Nakayama Hideki , Tanaka Takuya , Nagata Masashi , Takamune Yasuo , Kawahara Kenta , Nakagawa Yoshihiro , Yoshida Ryoji , Hirosue Akiyuki , Ogi Hidenao , Hiraki Akimitsu , Jono Hirofumi , Hamada Akinobu , Yoshida Koji , Nishimura Yasuharu , Nakamura Yusuke , Shinohara Masanori
Published: April 2023

Figure S1. Representative immunological monitoring assays detecting antigen-specific CTL responses.
Table S1 from Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
Authors: Huang Jing , Xu Binghe , Mo Hongnan , Zhang Weilong , Chen Xuelian , Wu Dawei , Qu Dong , Wang Xingyuan , Lan Bo , Yang Beibei , Wang Pei , Zhang Hongtu , Yang Qing , Jiao Yuchen
Published: April 2023

Sequence analysis summary of 23 whole exome sequenced esophageal carcinomas.
Figure S1-S4 from Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
Authors: Huang Jing , Xu Binghe , Mo Hongnan , Zhang Weilong , Chen Xuelian , Wu Dawei , Qu Dong , Wang Xingyuan , Lan Bo , Yang Beibei , Wang Pei , Zhang Hongtu , Yang Qing , Jiao Yuchen
Published: April 2023

supplementary figures
Supplemental Figures S1-5 from Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
Authors: Rojas Juan J. , Sampath Padma , Hou Weizhou , Thorne Steve H.
Published: April 2023

Supplemental Figures S1-5. S1: isotype controls and ctla-4 effects on viral replication; S2: effects of anti-CD25; S3: B18R effects on Treg and NK cells; S4: gating for T-cells and NK cells; S5: effects of IFNg depletion
Supplementary Figures S1-S14 from Livin Contributes to Tumor Hypoxia–Induced Resistance to Cytotoxic Therapies in Glioblastoma Multiforme
Authors: Hsieh Chia-Hung , Lin Yu-Jung , Wu Chung-Pu , Lee Hsu-Tung , Shyu Woei-Cherng , Wang Chi-Chung
Published: April 2023

Supplementary Figures S1-S14 S1. Q-PCR analysis of Livin mRNA levels in GBM8401 glioblastoma cells after normoxia, non-interrupted (Ni.) hypoxia (<1% O2) and cycling (Cy.) hypoxia (<1% O2); S2. Western blot analysis of Livin protein levels in GBM8401 glioblastoma cells after normoxia, non-interrupted (Ni.) hypoxia (<1% O2) and cycling (Cy.) hypoxia (<1% O2); S3. Representative images of microscopic GBM8401/hif-1-r. Top left, fluorescence image of DsRed reporter, indicating tumor cell localization within the brain; S4. Immunofluorescence imaging of Livin and HIF-1α expression in primary GBMs; S5. Livin mRNA levels in U251, U87 and GBM8401 cells for 24 hours with desferrioxamine (100 μM) or cobalt chloride (50 μM) incubation. *P < 0.001 compared with control; S6. Kinetics of luciferase activities in GBM8401 cells transfected with a lentiviral vector bearing a 2510-bp Livin promoter-driven luciferase reporter gene under hypoxic condition (<1% O2) for 72 hours; S7. The reporter activities of Livin promoter in HEK-293 and GBM8401 cells cultured in hypoxia for 24 hours in the absence or presence of YC-1 and in cells co-transfected with control or HIF-1α-ODD deletion mutant plasmids for 48 hours; S8. Surviving fraction for GBM8410 with or without Doxinduced Livin knockdown and receiving hypoxic stress (<1% O2), either noninterrupted (Ni.) or cycling (Cy.) hypoxia, followed by 4-Gy irradiation; S9. Caspase-3 activities in Livin-positive (GBM8401) cells and Livin-negative (H1299) cells incubated with 0, 10, 30 and 60 μM TAT-Lp15 together with 1 μM STA for 4 hours; S10. Percentages of apoptotic cells in Livin-positive (GBM8401) cells and Livin-negative (H1299) cells incubated with 0, 10, 30 and 60 μM TAT-Lp15 together with 1 μM STA for 4 hours; S11. Caspase-3 activities in GBM8401 cells with or without Livin knockdown incubated with 0, 10, 30 and 60 μM TAT-Lp15 together with 1 μM STA for 4 hours; S12. Percentages of apoptotic cells in GBM8401 cells with or without Livin knockdown incubated with 0, 10, 30 and 60 μM TAT-Lp15 together with 1 μM STA for 4 hours; S13. Surviving fraction and colony images for GBM8410 cells incubated with 0, 10, 20 and 30 μM TAT-Lp15 for 4 hours followed by 4-Gy irradiation (IR0; S14. The western blot data in Figure 1C (A) , 2A (B-E), 2C (F and G) and 4B (H) was quantified.
Supplementary Tables 1 and 2 from Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma
Authors: Ogura Michinori , Tobinai Kensei , Hatake Kiyohiko , Davies Andrew , Crump Michael , Ananthakrishnan Revathi , Ishibashi Taro , Paccagnella M. Luisa , Boni Joseph , Vandendries Erik , MacDonald David
Published: April 2023

Table S1. Dose Escalation of C (3 levels) or InO (2 levels) and Treatment Schedule Used to Determine the MTD Based on a Standard 3+3 Design; Table S2. AEs Leading to Permanent Discontinuation or Modification of the MTD
Supplementary Methods from Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma
Authors: Ogura Michinori , Tobinai Kensei , Hatake Kiyohiko , Davies Andrew , Crump Michael , Ananthakrishnan Revathi , Ishibashi Taro , Paccagnella M. Luisa , Boni Joseph , Vandendries Erik , MacDonald David
Published: April 2023

SUPPLEMENTARY METHODS
Supplemental Figure 1 from Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma
Authors: Amengual Jennifer E. , Johannet Paul , Lombardo Maximilian , Zullo Kelly , Hoehn Daniela , Bhagat Govind , Scotto Luigi , Jirau-Serrano Xavier , Radeski Dejan , Heinen Jennifer , Jiang Hongfeng , Cremers Serge , Zhang Yuan , Jones Simon , O'Connor Owen A.
Published: April 2023

Peripheral blood mononuclear cells (PBMCs) were separated from whole blood by Ficoll-Paque layering. (A) Concentration : effect relationship was determined for ACY-1215 at 24 and 48 hours in PBMCs. No cytotoxicity was observed after 24 and 48 hours of exposure. The IC50 was not reached at 24 and 48 hours. (B) Treatment of PBMCs with ACY-1215 1500 nM led to no induction of the UPR as demonstrated by Western blot analysis. (C) Dual targeting of protein degradation pathways with ACY-1215 and bortezomib led to no cytotoxicity in PBMCs and the combination is not synergistic. Cells were treated with increasing concentrations of ACY-1215 (0, 500, 1000, and 1500nM) plus bortezomib 3 nM for 48 hours. Synergy was calculated using Excess over Bliss where values greater than 10 represent synergy.
Supplementary Table 1 from Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non–Small Cell Lung Cancer
Authors: Thangavel Chellappagounder , Boopathi Ettickan , Liu Yi , McNair Christopher , Haber Alex , Perepelyuk Maryna , Bhardwaj Anshul , Addya Sankar , Ertel Adam , Shoyele Sunday , Birbe Ruth , Salvino Joseph M. , Dicker Adam P. , Knudsen Karen E. , Den Robert B.
Published: April 2023

supplementary Table 1
Supplementary Figures from Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non–Small Cell Lung Cancer
Authors: Thangavel Chellappagounder , Boopathi Ettickan , Liu Yi , McNair Christopher , Haber Alex , Perepelyuk Maryna , Bhardwaj Anshul , Addya Sankar , Ertel Adam , Shoyele Sunday , Birbe Ruth , Salvino Joseph M. , Dicker Adam P. , Knudsen Karen E. , Den Robert B.
Published: April 2023

Supplemental Figure 1. RB Regulates RB/E2F Target Gene Transcription and Restricts NSCLC Tumor Burden. Supplemental Figure 2. RB Promotes Cellular Senescence in NSCLC. Supplemental Figure 3. RB Dependent In Vitro Cellular Apoptosis in Response to CDK4/6 Inhibition in NSCLC. Supplemental Figure 4. Mitochondrial Protein SMAC Regulates NSCLC Apoptosis In Vitro. Supplemental Figure 5. Human Transcriptome Array Identifies FOXM1 and Survivin as RB/E2F Signatures. Supplemental Figure 6. RB Mediates Non-small Cell Lung Cancer Apoptosis via RB/IAP/SMAC/Caspase 3 signaling axis.
Supplemental Table 1 from Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions
Authors: Piesche Matthias , Ho Vincent T. , Kim Haesook , Nakazaki Yukoh , Nehil Michael , Yaghi Nasser K. , Kolodin Dmitriy , Weiser Jeremy , Altevogt Peter , Kiefel Helena , Alyea Edwin P. , Antin Joseph H. , Cutler Corey , Koreth John , Canning Christine , Ritz Jerome , Soiffer Robert J. , Dranoff Glenn
Published: April 2023

Supplemental Table 1. Targets identified in protein microarray screening with post-vaccination sera from AML patient 12.
Supplemental Figure Legend from Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non–Small Cell Lung Cancer
Authors: Thangavel Chellappagounder , Boopathi Ettickan , Liu Yi , McNair Christopher , Haber Alex , Perepelyuk Maryna , Bhardwaj Anshul , Addya Sankar , Ertel Adam , Shoyele Sunday , Birbe Ruth , Salvino Joseph M. , Dicker Adam P. , Knudsen Karen E. , Den Robert B.
Published: April 2023

Supplemental data legends
Supplementary table 4 from Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Authors: Kimbung Siker , Johansson Ida , Danielsson Anna , Veerla Srinivas , Egyhazi Brage Suzanne , Frostvik Stolt Marianne , Skoog Lambert , Carlsson Lena , Einbeigi Zakaria , Lidbrink Elisabet , Linderholm Barbro , Loman Niklas , Malmström Per-Olof , Söderberg Martin , Walz Thomas M. , Fernö Mårten , Hatschek Thomas , Hedenfalk Ingrid
Published: April 2023

Multivariable Cox proportional hazards analyses for relapse-free survival (RFS) and overall survival (OS) among patients with ER positive primary tumors in GOBO. Separate analyses are shown for all ER positive tumors and the subset of luminal A tumors. P<0.05 was considered significant.
Supplementary Table 3 from Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Authors: Kimbung Siker , Johansson Ida , Danielsson Anna , Veerla Srinivas , Egyhazi Brage Suzanne , Frostvik Stolt Marianne , Skoog Lambert , Carlsson Lena , Einbeigi Zakaria , Lidbrink Elisabet , Linderholm Barbro , Loman Niklas , Malmström Per-Olof , Söderberg Martin , Walz Thomas M. , Fernö Mårten , Hatschek Thomas , Hedenfalk Ingrid
Published: April 2023

Gene ontology analysis showing significantly enriched GO-terms for biological process among the significantly altered genes in breast cancer liver metastases compared to metastases from other sites.
Supplementary Table S4: Performance of models constructed with one omic only from Deep Learning–Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer
Authors: Chaudhary Kumardeep , Poirion Olivier B. , Lu Liangqun , Garmire Lana X.
Published: April 2023

Performance of models constructed with one omic only.
Supplementary Table 2 from Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Authors: Kimbung Siker , Johansson Ida , Danielsson Anna , Veerla Srinivas , Egyhazi Brage Suzanne , Frostvik Stolt Marianne , Skoog Lambert , Carlsson Lena , Einbeigi Zakaria , Lidbrink Elisabet , Linderholm Barbro , Loman Niklas , Malmström Per-Olof , Söderberg Martin , Walz Thomas M. , Fernö Mårten , Hatschek Thomas , Hedenfalk Ingrid
Published: April 2023

Genes differential expressed between liver metastases compared to other metastatic sites. Two class SAM analyses was performed within the subset of ER positive tumors using the site (liver versus other) of metastasis as supervising variable. Genes were considered significant at FDR=0.1.
Supplementary Table S3: Performance for cross-validation and confirmation cohorts when using alternative approaches, different normalizations, and different hyper-parameter values from Deep Learning–Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer
Authors: Chaudhary Kumardeep , Poirion Olivier B. , Lu Liangqun , Garmire Lana X.
Published: April 2023

Performance for cross-validation and for the confirmation cohorts when using alternative approaches, different normalizations and different hyper-parameter values.
Supplementary Table S2: ANOVA-based top features from three omics: mRNA, miR, and methylation from Deep Learning–Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer
Authors: Chaudhary Kumardeep , Poirion Olivier B. , Lu Liangqun , Garmire Lana X.
Published: April 2023

ANOVA-based top discriminative features from three omics.
Supplementary Figure legends from Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Authors: Kimbung Siker , Johansson Ida , Danielsson Anna , Veerla Srinivas , Egyhazi Brage Suzanne , Frostvik Stolt Marianne , Skoog Lambert , Carlsson Lena , Einbeigi Zakaria , Lidbrink Elisabet , Linderholm Barbro , Loman Niklas , Malmström Per-Olof , Söderberg Martin , Walz Thomas M. , Fernö Mårten , Hatschek Thomas , Hedenfalk Ingrid
Published: April 2023

Legends for Supplementary figures
Supplementary Table S1: Clinical characteristics of the HCC cohorts used in this study from Deep Learning–Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer
Authors: Chaudhary Kumardeep , Poirion Olivier B. , Lu Liangqun , Garmire Lana X.
Published: April 2023

Clinical characteristics of the HCC cohorts used in this study
Supplementary File S2: Description of results on differential tests of miRNAs and methylation from Deep Learning–Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer
Authors: Chaudhary Kumardeep , Poirion Olivier B. , Lu Liangqun , Garmire Lana X.
Published: April 2023

Description of results on differential tests of miRNAs and methylation
Supplementary Figure S2 from Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Authors: Kimbung Siker , Johansson Ida , Danielsson Anna , Veerla Srinivas , Egyhazi Brage Suzanne , Frostvik Stolt Marianne , Skoog Lambert , Carlsson Lena , Einbeigi Zakaria , Lidbrink Elisabet , Linderholm Barbro , Loman Niklas , Malmström Per-Olof , Söderberg Martin , Walz Thomas M. , Fernö Mårten , Hatschek Thomas , Hedenfalk Ingrid
Published: April 2023

Unsupervised HCL of the test cohort on normal tissue and breast cancer selective genes (gene lists from (33)): A) Normal Liver, B) Normal Breast; and C) breast cancer selective genes (gene list from (34)).
Supplementary Table 3 from Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
Authors: Rothenberg S. Michael , McFadden David G. , Palmer Edwin L. , Daniels Gilbert H. , Wirth Lori J.
Published: April 2023

Supplementary Table 3. Serum TSH values.
Supplementary Table 1 from Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
Authors: Rothenberg S. Michael , McFadden David G. , Palmer Edwin L. , Daniels Gilbert H. , Wirth Lori J.
Published: April 2023

Supplementary Table 1. Summary of Patient Study Data.
Supplementary Figure 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Authors: Ohue Yoshihiro , Kurose Koji , Mizote Yu , Matsumoto Hirofumi , Nishio Yumi , Isobe Midori , Fukuda Minoru , Uenaka Akiko , Oka Mikio , Nakayama Eiichi
Published: April 2023

Representative results of analyses on Th1, Th2, Th17 and TFH CD4 T cells, and resting and activated CD4 Tregs, and M- and PMN-MDSCs in PBMCs from an XAGE1 (GAGED2a) antibody-positive patient, KLU213 or from an XAGE1 (GAGED2a) antibody-negative patient, KLU320 by FACS.
Supplemental Figures 1-5 from Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non–Small Cell Lung Cancers In Vitro and In Vivo
Authors: Tao Zhen , Le Blanc Justin M. , Wang Chenguang , Zhan Tingting , Zhuang Hongqing , Wang Ping , Yuan Zhiyong , Lu Bo
Published: April 2023

Includes additional Western blots, isobolograms, and cell survival assays. Figure S1. (A) Western blots were performed on the three cell lines to analyze the levels of p-ERK, which is a key protein involved in cellular proliferation and growth; Figure S2. (A) MTS assays on additional cell lines (e.g. H23, SK-LU-1, and Calu-1) were performed with increasing concentrations of both MEKi and CDKi; Figure S3. . Cells were treated with various concentrations of GSK1120212 in combination with PD0332991 for 72 hours, and cell viability was measured by MTS assay (left); Figure S4. Isobologram for the combination of GSK1120212 with PD0332991 in A549 and H460 cell lines; Figure S5. MEK inhibitor enhances radiosensitivity of KRAS mutant NSCLC cell lines.
supplementary figure 1 from Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake
Authors: Trani Daniela , Yaromina Ala , Dubois Ludwig , Granzier Marlies , Peeters Sarah G.J.A. , Biemans Rianne , Nalbantov Georgi , Lieuwes Natasja , Reniers Brigitte , Troost Esther E.G.C. , Verhaegen Frank , Lambin Philippe
Published: April 2023

An example of distribution of hypoxia tracer HX4 (3 hours post injection) and FDG (2 hours post injection) in the same rhabdomyosarcoma bearing rat 20 hours apart, demonstrating large overlap between the tracers. White contours correspond to 30% of the GTV (magenta contours) with the highest SUV. Dice similarity coefficient is 0.79 for this example.
Supplementary Figure 6 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Authors: Pham Christina D. , Flores Catherine , Yang Changlin , Pinheiro Elaine M. , Yearley Jennifer H. , Sayour Elias J. , Pei Yanxin , Moore Colin , McLendon Roger E. , Huang Jianping , Sampson John H. , Wechsler-Reya Robert , Mitchell Duane A.
Published: April 2023

Gating strategy for Ptch1 MB tumors.
Supplementary Figure 2 from Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer
Authors: Abdel-Fatah Tarek M. , Ball Graham , Lee Andrew H.S. , Pinder Sarah , MacMilan R. Douglas , Cornford Eleanor , Moseley Paul M. , Silverman Rafael , Price James , Latham Bruce , Palmer David , Chan Arlene , Ellis Ian O. , Chan Stephen Y.T.
Published: April 2023

Supplementary Figure 2. Receiver operating characteristic (ROC) analysis of pathological complete response (pCR), revised pathological TNM stage (yp-TNM stage), Clinical-Pathologic Scoring System (CPS) score and CPS-Oestrogen receptor-histological grade (CPS-EG) were performed for predicting breast cancer specific survival in the training (A), internal validation (B), external validation (C) and combined three cohorts (D).
Supplementary Figure 1 from Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer
Authors: Abdel-Fatah Tarek M. , Ball Graham , Lee Andrew H.S. , Pinder Sarah , MacMilan R. Douglas , Cornford Eleanor , Moseley Paul M. , Silverman Rafael , Price James , Latham Bruce , Palmer David , Chan Arlene , Ellis Ian O. , Chan Stephen Y.T.
Published: April 2023

Supplementary Figure 1. Kaplan Meier curves showing disease free survival (DFS) in the training (upper panels), internal validation (middle panels) and external validation (lower panels) cohorts stratified according to the number of lymph node (LN) metastases (i), presence of lympho-vascular invasion (LVI; ii), absence of fibrosis (iii) the percentage reduction in primary tumour size (iv).
Supplemental Figure Legend from Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer
Authors: Abdel-Fatah Tarek M. , Ball Graham , Lee Andrew H.S. , Pinder Sarah , MacMilan R. Douglas , Cornford Eleanor , Moseley Paul M. , Silverman Rafael , Price James , Latham Bruce , Palmer David , Chan Arlene , Ellis Ian O. , Chan Stephen Y.T.
Published: April 2023

supplemental figure legend.
Supplementary Figure S1 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
Authors: Herman Sarah E.M. , Mustafa Rashida Z. , Jones Jade , Wong Deanna H. , Farooqui Mohammed , Wiestner Adrian
Published: April 2023

Supplementary Figure S1: Effect of in vitro or in vivo ibrutinib treatment on cell migration.
Supplementary Table S1 from Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer
Authors: Lee Se-Ra , Roh Yun-Gil , Kim Seon-Kyu , Lee Ju-Seog , Seol So-Young , Lee Hyun-Hee , Kim Won-Tae , Kim Wun-Jae , Heo Jeonghoon , Cha Hee-Jae , Kang Tae-Hong , Chung Jin Woong , Chu In-Sun , Leem Sun-Hee
Published: April 2023

Supplementary Table S1. Prediction of activated upstream regulators during disease progression.
Supplementary Tables 1-2, Supplementary Methods, Supplementary Figure Legend from Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
Authors: Sarantopoulos John , Shapiro Geoffrey I. , Cohen Roger B. , Clark Jeffrey W. , Kauh John S. , Weiss Glen J. , Cleary James M. , Mahalingam Devalingam , Pickard Michael D. , Faessel Hélène M. , Berger Allison J. , Burke Kristine , Mulligan George , Dezube Bruce J. , Harvey R. Donald
Published: April 2023

Supplemental Table 1: Treatment-related AEs experienced by {greater than or equal to}10% of patients on any schedule, and treatmentrelated grade {greater than or equal to}3 AEs reported in at least 1 patient; Supplemental Table 2: Summary of hepatotoxicities reported with pevonedistat on each dosing schedule and overa ll
Supplementary Figure Legends from Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models
Authors: Francis David M. , Huang Shyhmin , Armstrong Eric A. , Werner Lauryn R. , Hullett Craig , Li Chunrong , Morris Zachary S. , Swick Adam D. , Kragh Michael , Lantto Johan , Kimple Randall J. , Harari Paul M.
Published: April 2023

Supplementary Figure Legends
Supplemental Figure S3 from 18F-FAZA PET Imaging Response Tracks the Reoxygenation of Tumors in Mice upon Treatment with the Mitochondrial Complex I Inhibitor BAY 87-2243
Authors: Chang Edwin , Liu Hongguang , Unterschemmann Kerstin , Ellinghaus Peter , Liu Shuanglong , Gekeler Volker , Cheng Zhen , Berndorff Dietmar , Gambhir Sanjiv S.
Published: April 2023

Supplemental Figure S3. Graph derived from the scientific literature (24) that shows a linear correlation between 18F-FPP(RGD)2 uptake and tumor volume in HCT116 human colon cancer xenografts.
Supplemental figure 4 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
Authors: van der Sluis Tetje C. , van Duikeren Suzanne , Huppelschoten Suzanna , Jordanova Ekaterina S. , Beyranvand Nejad Elham , Sloots Arjen , Boon Louis , Smit Vincent T.H.B.M. , Welters Marij J.P. , Ossendorp Ferry , van de Water Bob , Arens Ramon , van der Burg Sjoerd H. , Melief Cornelis J.M.
Published: April 2023

Supplemental figure 4) TNFÃŽÂ± sensitization for chemotherapy is dose dependent.
Supplementary Figure 6 from Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice
Authors: Kim Sun-Jin , Lee Ho Jeong , Kim Mark Seungwook , Choi Hyun Jin , He Junqin , Wu Qiuyu , Aldape Kenneth , Weinberg Jeffrey S. , Yung W.K. Alfred , Conrad Charles A. , Langley Robert R. , Lehembre François , Regenass Urs , Fidler Isaiah J.
Published: April 2023

Supplementary Figure 6. Effects of treatment on glioblastoma-associated blood vessels.
Supplemental Table 4 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
Authors: Bikos Vasilis , Karypidou Maria , Stalika Evangelia , Baliakas Panagiotis , Xochelli Aliki , Sutton Lesley-Ann , Papadopoulos George , Agathangelidis Andreas , Papadopoulou Evdoxia , Davis Zadie , Algara Patricia , Kanellis George , Traverse-Glehen Alexandra , Mollejo Manuela , Anagnostopoulos Achilles , Ponzoni Maurilio , Gonzalez David , Pospisilova Sarka , Matutes Estella , Piris Miguel Angel , Papadaki Theodora , Ghia Paolo , Rosenquist Richard , Oscier David , Darzentas Nikos , Tzovaras Dimitrios , Belessi Chrysoula , Hadzidimitriou Anastasia , Stamatopoulos Kostas
Published: April 2023

Counts and distribution of confirmed and unconfirmed replacement and silent mutations per IGHV gene group and V-subregion. Respective R/S ratios
Supplemental Table 2 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
Authors: Bikos Vasilis , Karypidou Maria , Stalika Evangelia , Baliakas Panagiotis , Xochelli Aliki , Sutton Lesley-Ann , Papadopoulos George , Agathangelidis Andreas , Papadopoulou Evdoxia , Davis Zadie , Algara Patricia , Kanellis George , Traverse-Glehen Alexandra , Mollejo Manuela , Anagnostopoulos Achilles , Ponzoni Maurilio , Gonzalez David , Pospisilova Sarka , Matutes Estella , Piris Miguel Angel , Papadaki Theodora , Ghia Paolo , Rosenquist Richard , Oscier David , Darzentas Nikos , Tzovaras Dimitrios , Belessi Chrysoula , Hadzidimitriou Anastasia , Stamatopoulos Kostas
Published: April 2023

IGH rearrangements'intraclonal diversification characteristics. Counts, distribution, hotspot targeting of confirmed/unconfirmed mutations and respective amino acid changes across gene groups and IGHV subregions.
Supplementary Table Set - S1-S10 from Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Authors: Burstein Matthew D. , Tsimelzon Anna , Poage Graham M. , Covington Kyle R. , Contreras Alejandro , Fuqua Suzanne A.W. , Savage Michelle I , Osborne C. Kent , Hilsenbeck Susan G. , Chang Jenny C. , Mills Gordon B. , Lau Ching C. , Brown Powel H.
Published: April 2023

Table S1. Differentially Expressed Genes for NMF Cluster 1 (LAR). Table S2. Differentially Expressed Genes for NMF Cluster 2 (MES). Table S3. Differentially Expressed Genes for NMF Cluster 3 (BLIS). Table S4. Differentially Expressed Genes for NMF Cluster 4 (BLIA). Table S5. Enrichment of discovery set differentially expressed genes in the validation set. Table S6. All significant pathways in either the Discovery or Validation Sets for NMF Cluster 1 (LAR). Table S7. All significant pathways in either the Discovery or Validation Sets for NMF Cluster 2 (MES). Table S8. All significant pathways in either the Discovery or Validation Sets for NMF Cluster 3 (BLIS). Table S9. All significant pathways in either the Discovery or Validation Sets for NMF Cluster 4 (BLIA). Table S10. Pathway Overlap for the NMF Clusters' Discovery Set Pathways.
Supplementary Figure 1 from Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer
Authors: Fankhauser Matthew , Tan Yuen , Macintyre Geoff , Haviv Izhak , Hong Matthew K.H. , Nguyen Anne , Pedersen John S. , Costello Anthony J. , Hovens Christopher M. , Corcoran Niall M.
Published: April 2023

PDF file - 148KB, Figure S1. Mean + SEM concentration of indicated steroids measured in the conditioned media derived from BPH, hormone na�ve CaP or HRPC when cultured in the presence of cholesterol, progesterone, DHEA or testosterone at a concentration of 10 ng/ml for 96 hr.
Supplementary Table 1 from Triple-Negative versus Non–Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study
Authors: Podo Franca , Santoro Filippo , Di Leo Giovanni , Manoukian Siranoush , de Giacomi Clelia , Corcione Stefano , Cortesi Laura , Carbonaro Luca A. , Trimboli Rubina M. , Cilotti Anna , Preda Lorenzo , Bonanni Bernardo , Pensabene Matilde , Martincich Laura , Savarese Antonella , Contegiacomo Alma , Sardanelli Francesco
Published: April 2023

Diagnostic performance of screening modalities for invasive triple negative breast cancers (TNBCs) versus non-TNBCs
Supplementary Figure S4 from Autocrine Activation of CHRM3 Promotes Prostate Cancer Growth and Castration Resistance via CaM/CaMKK–Mediated Phosphorylation of Akt
Authors: Wang Naitao , Yao Ming , Xu Jin , Quan Yizhou , Zhang Kaiqing , Yang Ru , Gao Wei-Qiang
Published: April 2023

Supplementary Figure S4. Calcium influx induced by various concentrations of acetylcholine or carbachol.
Supplementary Figure S3 from Autocrine Activation of CHRM3 Promotes Prostate Cancer Growth and Castration Resistance via CaM/CaMKK–Mediated Phosphorylation of Akt
Authors: Wang Naitao , Yao Ming , Xu Jin , Quan Yizhou , Zhang Kaiqing , Yang Ru , Gao Wei-Qiang
Published: April 2023

Supplementary Figure S3. CHRM3 is up-regulated in CRPC cells.
Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Authors: Doñate Fernando , Raitano Arthur , Morrison Kendall , An Zili , Capo Linnette , Aviña Hector , Karki Sher , Morrison Karen , Yang Peng , Ou Jimmy , Moriya Ryuichi , Shostak Yuriy , Malik Faisal , Nadell Rossana , Liu Wendy , Satpayev Daulet , Atkinson John , Joseph Ingrid B.J. , Pereira Daniel S. , Challita-Eid Pia M. , Stover David R.
Published: April 2023

Supplemental Table 2. Comparability of Anti-ENPP3 ADC Produced in Hybridoma or CHO Cells
Supplemental Figures 1-4 from Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer
Authors: Wen Yunfei , Graybill Whitney S. , Previs Rebecca A. , Hu Wei , Ivan Cristina , Mangala Lingegowda S. , Zand Behrouz , Nick Alpa M. , Jennings Nicholas B. , Dalton Heather J. , Sehgal Vasudha , Ram Prahlad , Lee Ju-Seog , Vivas-Mejia Pablo E. , Coleman Robert L. , Sood Anil K.
Published: April 2023

Supplementary Figures 1-4. S1: FR_ expression and antitumor activities of MORAB-003; S2: Modest apoptosis-inducing effect of MORAB-003; S3: Autophagy induced by MORAB-003 in IGROV1 models in vivo and in vitro; S4: Autophagic flux induced by MORAB-003 and the association of FOLR1 gene with clinical outcome in human uterine cancer.